New biomarker for early prediction of response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step toward optimizing this promising therapy. The results of the study were recently published in the journal Frontiers in Immunology.